Últimas noticias sobre Okeanis Eco Tankers (NYSE:ECO) Bolsa

Okeanis Eco Tankers

Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers, and eight VLCC tankers.

Okeanis Eco Tankers Corp

Columbia Research Enhanced Emerging Economies ETF

electroCore Inc

ELCORA ADVANCED MAT ORD by Elcora Advanced Materials Corp.

Elcora Advanced Materials Corp

Pacer Emerging Markets Cash Cows 100 ETF

ECO INNOVATION GRP INC by Eco Innovation Group, Inc.

Eco Innovation Group Inc

News

Guidance

CRDO

Credo Technology Group Sees Q3 Revenue $115M-$125M Vs $86.042M Est.

Recent research in Utah highlights <a href="http://benzinga.com/cannabis">cannabis</a> as a potential game-changer in pain management. A study by Management Science Associates (MSA) found a 53% drop in opioid prescriptions among chronic pain patients who used cannabis between 2021 and 2024.
The <a href="https://www.utah.gov/pmn/files/1194861.pdf">study</a>, presented at a Medical Cannabis Policy Advisory Board meeting, examined data from 186 patients. It revealed that 84.4% of participants reduced opioid use after starting cannabis treatment, with the greatest reduction seen in neuropathic pain (73.5%).
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="875" height="424" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02143907/utahopioidscannabis.png" alt="" class="wp-image-673112" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02143907/utahopioidscannabis.png 875w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02143907/utahopioidscannabis-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02143907/utahopioidscannabis-768x372.png 768w" sizes="(max-width: 875px) 100vw, 875px" /><figcaption class="wp-element-caption">Source: Management Science Associates (MSA)</figcaption></figure>
<h3 class="wp-block-heading">Insights From Utah And Minnesota Studies</h3>
Notably, vapes (67.6%), gummies (53.3%) and tinctures (19%) were the preferred products. However, chronic headache and orofacial pain patients experienced increased opioid use, underscoring the need for targeted treatments.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
MSA noted that a similar study in <a href="http://benzinga.com/topic/minnesota-cannabis">Minnesota</a> reported a 30% reduction in opioid prescriptions. While acknowledging limitations such as the three-year timeframe, the MSA study says, &#8220;Cannabis may offer a safer pain management alternative, helping reduce opioid dependency and associated risks.&#8221;
<h3 class="wp-block-heading">What Utah's Study Means For Medical Marijuana Markets</h3>
Utah&#8217;s regulated cannabis market offers significant potential, though it faces challenges. As of October 2024, the state reported over 90,000 registered medical cannabis patients, primarily using cannabis to manage pain, <a href="https://hempgazette.com/news/utah-opioids-cannabis-hg2353">according</a> to Hemp Gazette.
Patients spent<a href="https://www.benzinga.com/markets/cannabis/24/10/41467589/is-utah-ready-for-legal-weed-half-the-state-says-yes-whats-the-market-potential"> an average of $109.10 per month</a>, close to the national average, but high product prices and strict regulations push many to out-of-state markets. Neighboring Colorado and Nevada offer products at $8.37 and $8.58 per gram, respectively, compared to Utah's $12.15.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39256426/heres-how-to-enhance-marijuana-therapies-kindlymd-and-curaleaf-collab-provide-more-resources-and">Here&#8217;s How To Enhance Marijuana Therapies: KindlyMD And Curaleaf Collab Provide More Resources And Information To Utah Patients</a>
The state's evolving regulatory framework, established after voters approved medical marijuana in 2018, has spurred growth. <a href="https://www.benzinga.com/markets/cannabis/24/10/41467589/is-utah-ready-for-legal-weed-half-the-state-says-yes-whats-the-market-potential">Recent polling</a> by Noble Predictive Insights revealed that 50% of Utahns now support adult-use legalization, up from previous years. Younger voters, aged 18-34, lead this shift with 60% in favor of adult-use cannabis.
These developments could reshape Utah's market dynamics. Multi-state operators like Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) and Columbia Care (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBSTF#OTC">CBSTF</a>), already active in the state, stand to benefit if patient numbers grow or regulations ease. Companies focusing on effective, affordable products, such as vapes, gummies and tinctures, are well-positioned to capitalize on the <a href="https://www.benzinga.com/markets/cannabis/24/01/36578723/huge-study-reveals-cannabis-provides-similar-pain-relief-benefits-as-opioids-without-negative-co">increasing demand for cannabis-based pain management solutions</a>.
Additionally, the shift towards cannabis for pain management <a href="https://www.benzinga.com/markets/cannabis/24/09/40900626/legal-medical-cannabis-could-save-us-healthcare-29b-annually-new-study-finds">may influence healthcare policies and insurance coverage</a>. As more patients opt for cannabis over opioids, insurers might expand coverage for medical cannabis treatments. This potential policy change could further stimulate market growth.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42146502/us-overdose-deaths-decline-as-fentanyl-potency-weakens-harm-reduction-expands">US Overdose Deaths Decline As Fentanyl Potency Weakens, Harm Reduction Expands</a></li>
</ul>

Cannabis

Health Care

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

Cannabis Cuts Opioid Prescriptions By 53%, Utah Study Suggests

Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. The company reported quarterly sales of $72.000 million which beat the analyst consensus estimate of $66.789 million by 7.80 percent. This is a 63.51 percent increase over sales of $44.035 million the same period last year.

Earnings

Earnings Beats

Credo Technology Group Q2 2025 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $72.000M Beat $66.789M Estimate

<h3>Gainers</h3>
<ul>
<li>Vision Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) stock rose 20.9% to $2.66 during Monday's pre-market session. The market value of their outstanding shares is at $2.4 million. </li>
<li>MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) stock rose 14.69% to $22.95. The company's market cap stands at $7.1 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) shares increased by 10.27% to $1.61. The company's market cap stands at $85.2 million. </li>
<li>Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) stock rose 8.61% to $3.91. The market value of their outstanding shares is at $42.2 million. </li>
<li>Mynd.ai (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYND#AMEX">MYND</a>) shares moved upwards by 8.2% to $3.16. The company's market cap stands at $144.2 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares rose 7.07% to $0.87. The company's market cap stands at $18.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mondee Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOND#NASDAQ">MOND</a>) shares decreased by 22.6% to $0.55 during Monday's pre-market session. The market value of their outstanding shares is at $48.0 million. </li>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) shares decreased by 14.9% to $0.4. The market value of their outstanding shares is at $20.2 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares declined by 8.94% to $0.89. The company's market cap stands at $30.9 million. </li>
<li>Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) shares fell 8.68% to $18.75. The company's market cap stands at $1.1 billion. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) stock decreased by 8.61% to $3.93. The market value of their outstanding shares is at $45.1 million. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) stock decreased by 6.68% to $1.68. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIEV

AMBO

ECDA

FOSL

ISPO

MNSO

MOND

MYND

SPHL

VMAR

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock moved upwards by 227.8% to $7.08 during Monday's pre-market session. The market value of their outstanding shares is at $32.4 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock moved upwards by 50.22% to $5.04. The market value of their outstanding shares is at $170.9 million. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) stock rose 40.26% to $28.11. The market value of their outstanding shares is at $3.0 billion. </li>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) shares moved upwards by 36.12% to $5.2. The market value of their outstanding shares is at $254.1 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock moved upwards by 22.44% to $9.0. The company's market cap stands at $71.3 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares moved upwards by 19.25% to $12.88. The market value of their outstanding shares is at $106.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSGU#NASDAQ">BTSGU</a>) stock declined by 16.9% to $59.1 during Monday's pre-market session. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) stock decreased by 16.57% to $1.79. The company's market cap stands at $3.4 million. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) stock fell 9.45% to $1.15. The company's market cap stands at $27.6 million. </li>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock decreased by 8.24% to $3.01. The company's market cap stands at $127.9 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares declined by 7.84% to $0.36. The company's market cap stands at $6.0 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 7.53% to $2.7. The company's market cap stands at $31.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXI

BMRA

BTSGU

CABA

CRVO

NVCR

PPBT

RNXT

RPTX

SCNX

SNTI

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares increased by 58.7% to $0.76 during Monday's pre-market session. The company's market cap stands at $3.3 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>JE Cleantech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) shares rose 56.3% to $1.86. The market value of their outstanding shares is at $9.8 million. </li>
<li>KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) stock moved upwards by 41.37% to $1.64. The company's market cap stands at $351.3 million. </li>
<li>Ocean Power Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) stock moved upwards by 39.66% to $0.7. The market value of their outstanding shares is at $88.1 million. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) stock rose 24.65% to $4.55. The market value of their outstanding shares is at $105.8 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares moved upwards by 22.24% to $0.82. The company's market cap stands at $20.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares declined by 11.3% to $19.55 during Monday's pre-market session. The company's market cap stands at $2.3 billion. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) stock declined by 10.91% to $0.73. The market value of their outstanding shares is at $6.9 million. </li>
<li>Primega Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) stock fell 9.25% to $2.16. The company's market cap stands at $51.8 million. </li>
<li>Himalaya Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSHP#NYSE">HSHP</a>) stock fell 9.18% to $5.64. The company's market cap stands at $247.5 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock declined by 6.95% to $0.67. The market value of their outstanding shares is at $10.0 million. </li>
<li>Mynaric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) stock declined by 6.32% to $1.3. The company's market cap stands at $32.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EHGO

HOVR

HSHP

JCSE

KULR

MYNA

OPTT

PGHL

SGBX

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Mobilicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOB#NASDAQ">MOB</a>) shares moved upwards by 30.6% to $2.43 during Monday's pre-market session. The company's market cap stands at $15.4 million. </li>
<li>Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) stock rose 23.97% to $1.22. The market value of their outstanding shares is at $94.2 million. </li>
<li>Airship AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AISP#NASDAQ">AISP</a>) shares moved upwards by 19.87% to $3.74. The company's market cap stands at $102.0 million. </li>
<li>Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) shares increased by 18.15% to $22.13. The market value of their outstanding shares is at $183.6 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 17.64% to $1.8. The company's market cap stands at $55.0 million. </li>
<li>Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares increased by 14.89% to $37.5. The market value of their outstanding shares is at $21.9 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) shares decreased by 14.3% to $2.27 during Monday's pre-market session. The market value of their outstanding shares is at $146.5 million. </li>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock decreased by 14.29% to $0.96. The company's market cap stands at $61.0 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) stock fell 12.87% to $0.6. The market value of their outstanding shares is at $13.9 million. </li>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) stock fell 10.32% to $6.35. The company's market cap stands at $386.2 million. </li>
<li>CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) stock decreased by 8.78% to $2.91. The market value of their outstanding shares is at $20.0 million. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares decreased by 7.31% to $3.3. The company's market cap stands at $3.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AISP

ARBK

IDAI

MOBX

OBLG

ONDS

SMCI

TDTH

UMAC

12 Information Technology Stocks Moving In Monday's Pre-Market Session

WIIM

BILL

BILL shares are trading lower after the company announced a $1.0 billion offering of convertible senior notes due 2030.

BILL expects to use a portion of the net proceeds to pay the cost of the capped call transactions described below, to repurchase a portion of its outstanding convertible senior notes due 2025 and/or convertible senior notes due 2027 (together, the "Existing Notes") and to repurchase up to $200 million of shares of BILL's common stock. BILL intends to use the remaining net proceeds for general corporate purposes, which may include additional repurchases of the Existing Notes from time to time following the offering, or the repayment at maturity, of the Existing Notes, additional repurchases of the common stock, working capital, capital expenditures and potential acquisitions and strategic transactions.

Offerings

BILL Holdings Proposes To Offer $1B Of Convertible Senior Notes Due 2030

Management

Fluor Chief Financial Officer Joe Brennan to Retire, Effective Jul. 1; John Regan Appointed Successor, Effective Mar. 1

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA&#xAE; (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults. The patient was treated at Moffitt Cancer Center, one of Adaptimmune's Authorized Treatment Centers (ATCs) and a leader in sarcoma research and treatment.

Biotech

General

ADAP

Adaptimmune Therapeutics Announces That The First Patient Has Been Treated With TECELRA; Dosing Marks A Milestone For First Engineered Cell Therapy Approved In The U.S. For A Solid Tumor Cancer, Synovial Sarcoma

VXRT

Vaxart Completes Enrollment Of The Sentinel Cohort In Its Phase 2b Study Of Its  COVID-19 Oral Pill Vaccine Candidate

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

SOAR

Volato Unveils Patent-Pending Bitcoin Mining Technology, Transforming Aviation's $2.4B Market By Harnessing Underutilized Aircraft Resources To Generate Cryptocurrency, Boost Revenue, And Support Sustainability Efforts Through Advanced Computing At High Altitudes

<a href="https://www.justice.gov/opa/pr/gen-digital-pays-551m-false-claims-act-judgment-knowing-overcharges-general-services">https://www.justice.gov/opa/pr/gen-digital-pays-551m-false-claims-act-judgment-knowing-overcharges-general-services</a>
&nbsp;
Gen Digital Inc. (formerly known as Symantec Corp.), located in Tempe, Arizona, paid $55.1 million to satisfy a judgment, concluding a decade of False Claims Act litigation. The judgment required the company to pay $16.1 million in damages and $36.8 million in civil penalties, plus post-judgment interest and costs.
"The department will hold accountable contractors that knowingly overcharge the United States to enrich themselves," said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department's Civil Division. "The years spent litigating this case and taking it to trial demonstrate the department's steadfast commitment to protecting taxpayer funds."
Following a four-week bench trial in February and March 2022, the trial court found Symantec liable for making knowing false claims to the United States when it mispresented its commercial sales practices during the negotiation and subsequent performance of a General Services Administration (GSA) contract. In particular, the court concluded that Symantec made false statements to GSA during contractual negotiations in 2006 and early-2007 and continued to falsely certify throughout the performance of the contract through Sept. 30, 2012, that its disclosures of its commercial sales practices were current, accurate and complete. The false disclosures induced GSA to accept and then continue to pay higher prices than it would have had it known of Symantec's actual commercial pricing practices.
The court also found that Symantec continuously violated the Price Reduction Clause, a standard term in these types of Multiple Award Schedule contracts that requires the contractor throughout performance of the contract to maintain GSA's price position in relation to an identified customer or category of customer agreed upon in contract negotiations. These violations deprived the United States of discounts to which it was entitled.
"The trial team secured a $55 million judgment that holds accountable a contractor who intentionally tried to overbill the government," said U.S. Attorney Matthew M. Graves for the District of Columbia. "Because these schemes steal taxpayer dollars, the United States Attorney's Office for the District of Columbia will be steadfast in its efforts to bring fraudsters to justice no matter the complexity of the matter, pursuing them through trial, if necessary, to secure a just outcome."
"The United States deserves fair prices and accurate information from GSA contractors," said GSA Deputy Inspector General Robert C. Erickson. "This outcome is the result of hard work and dedication by a cross-functional team from the U.S. Department of Justice, GSA and GSA Office of Inspector General."
Gen Digital's payment ends a lawsuit filed under the qui tam or whistleblower provision of the False Claims Act, which permits private parties to file suit on behalf of the United States for false claims and share in a portion of the government's recovery. The Act permits the United States to intervene and take over responsibility for litigating these cases, as the United States did here. The qui tam case is captioned United States ex rel. Morsell v. Symantec Corp.,&nbsp;Civ. A. No.&nbsp;12-0800 (DDC), and was brought by Lori Morsell, who administered the contract at issue for Symantec. Her share of the recovery has not yet been determined.
This successful litigation was a coordinated effort between the Civil Division's Commercial Litigation Branch, Fraud Section, and the U.S. Attorney's Office for the District of Columbia, with assistance from GSA's Office of General Counsel and Office of Inspector General.
Senior Trial Counsel Daniel Schiffer and Trial Attorney F. Elias Boujaoude of the Justice Department's Civil Division and Civil Chief Brian P. Hudak for the District of Columbia handled the matter.

Legal

Gen Digital Pays $55.1M False Claims Act Judgment for Knowing Overcharges to General Services Administration After Government Prevails at Trial

Bank of America analysts shared a positive outlook for stocks in 2025 during Monday&#8217;s conference call on the <a href="https://www.benzinga.com/topic/expert-ideas">economic and market forecast.</a>
According to the bank, the S&amp;P 500 Index—as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—will climb to 6,666 by the end of 2025, marking a 10% increase from current levels. The forecast underscores confidence in productivity gains, resilient corporate earnings, and strategic sector rotation.
<h3 class="wp-block-heading">16 Years Of S&amp;P 500: From 666 To 6,666</h3>
"We are expecting another good year for equities," said Savita Subramanian, head of U.S. equity strategy at Bank of America. "Our forecast is basically a move from 666 in 2009 to 6,666 in 2025." 
This translates to an annualized return of approximately 10%, driven by robust earnings growth and broader participation across sectors.
The equity outlook for 2025 leans heavily on a projected 13% corporate earnings growth. 
"Although we do believe that 2025 will be a year of rotation rather than just buy the index," Subramanian indicated, hinting at a focus on cyclical stocks as investors seek opportunities beyond mega-cap tech.
Read Also: <a href="https://www.benzinga.com/24/11/42246831/morgan-stanley-sounds-alarm-for-markets-in-2025-sp-500-is-extremely-expensive">Morgan Stanley Sounds Alarm For Markets In 2025: &#8216;S&amp;P 500 Is Extremely Expensive&#8217;</a>
<h3 class="wp-block-heading">Sector Rotation and Valuation Themes</h3>
Bank of America's analysis points to cyclicals, particularly financials, energy, and consumer sectors, as key outperformers in 2025. 
Subramanian said that &#8220;the average stock is more attractive than the overall index,&#8221; citing the sharp gap between equal-weighted and cap-weighted S&amp;P 500 valuations.
Analysts at Bank of America highlighted opportunities in large-cap value stocks – as broadly tracked by the Vanguard S&amp;P 500 Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOOV#NYSE">VOOV</a>) – which they view as well-positioned to weather inflation and interest rate uncertainties. 
&#8220;The key risk under Trump 2.0 is the potential for higher inflation and higher long term interest rates. Our favorite cohort of the S&amp;P 500 is large cap value,&#8221; Subramanian said.
Small caps are expected to outperform large-cap counterparts during the first year of Donald Trump&#8216;s second term.
&#8220;We think the narrative on small caps as the biggest potential outperform,&#8221; analyst Jill Carey Hall said.
However, she indicated that if tariffs and immigration policies are enacted as proposed, especially with a front-loaded approach, they could pose a significantly greater risk to small-cap stocks.
&#8220;Recently proposed tariffs on Canada and Mexico could be a 7% hit to Russell earnings,&#8221; the analyst added. 
<h3 class="wp-block-heading">Productivity and Economic Growth</h3>
Economist Aditya Bhave continues to predict a strong U.S. economy, with productivity gains driving GDP growth to around 2% in 2025. 
"Productivity has accelerated," Bhave said. "We're now on a faster trend growth rate since the start of the pandemic than we were in the previous cycle."
While inflation is moderating, Bank of America warned of persistent risks. "We expect a few tenths extra inflation from tariffs and underlying inflation even setting aside policy changes as being a little bit sticky," Bhave stated.
<h3 class="wp-block-heading">Fed Policy And Risks</h3>
The Federal Reserve is expected to cut rates three times in 2025, bringing the terminal rate to 3.75-4%, according to Bank of America. 
However, Bhave cautioned about uncertainties tied to inflation and trade policy, particularly the potential impact of tariffs.
"Tariffs could add a few tenths to inflation, particularly against China, though FX could offset some of the impact," Bhave said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42273230/stellantis-market-value-halves-in-2024-why-ceo-tavares-exit-could-take-things-from-bad-to-worse">Stellantis Market Value Halves In 2024: Why CEO Tavares&#8217; Exit Could Take Things From Bad To Worse</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Federal Reserve

ETFs

VOOV

S&P 500 At 6,666 In 2025? Bank Of America Predicts 'Another Good Year For Equities'

<a href="https://www.federalreserve.gov/newsevents/speech/waller20241202a.htm" title="https://www.federalreserve.gov/newsevents/speech/waller20241202a.htm">https://www.federalreserve.gov/newsevents/speech/waller20241202a.htm</a>

Fed's Waller Says Yield Curve Can Be Inverted For Good Reasons If Markets Think Inflation And Therefore Rates Will Be Lower In The Future

<a href="https://ipsearch.ipaustralia.gov.au/patents/2018237549" title="https://ipsearch.ipaustralia.gov.au/patents/2018237549">https://ipsearch.ipaustralia.gov.au/patents/2018237549</a>

VCNX

Vaccinex Has Been Granted Australian Patent Number 2018237549 Titled "Treatment Of Cancer With A Semaphorin-4d Antibody In Combination With An Epigenetic Modulating Agent"

Kelly Slater, the 11-time World Surf League champion, recently joined the growing conversation around psychedelics. In an <a href="https://www.si.com/onsi/everyday-warrior-nation/everyday-warrior-podcast/kelly-slater-on-psychedelics-the-emerging-frontier-for-mental-health-and-human-performance">appearance</a> on the Everyday Warrior podcast, Slater discussed their transformative <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">potential for mental health</a> and human performance. 
Widely considered the greatest surfer of all time, Slater's endorsement of psychedelics, when used responsibly, marks a significant shift in how these substances are perceived, moving from counterculture to a legitimate tool for healing and personal growth.
<h3 class="wp-block-heading">Science Behind Psychedelic Therapy</h3>
Research into psychedelics, particularly <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and <a href="https://www.benzinga.com/topic/mdma">MDMA</a>, has gained momentum in recent years. Clinical studies from prestigious institutions like Johns Hopkins University show that psilocybin can effectively reduce symptoms of depression and anxiety, especially in treatment-resistant cases. Similarly, MDMA-assisted therapy has received FDA "breakthrough therapy" status for its success in treating PTSD.
Slater, a vocal advocate for wellness, agrees with the growing evidence. "Like a medicine of all types, used properly with the right approach is beneficial." He highlights the importance of a structured, medically supervised environment to ensure that psychedelics can be used safely and effectively.
<h3 class="wp-block-heading">Psychedelics And Peak Performance</h3>
While Slater has historically been cautious about drugs, he acknowledges that psychedelics can be a powerful tool for self-discovery and peak performance when used responsibly. "It's about opening up your mind in a safe and controlled way to improve your mental state and performance," he said.
Beyond healing trauma, psychedelics are increasingly used to enhance human performance. <a href="https://www.benzinga.com/markets/cannabis/24/11/41814007/pro-golfers-turn-to-psychedelics-for-focus-boost-and-anxiety-relief">Athletes</a> and entrepreneurs alike are experimenting with psychedelics for creativity, focus, and flow. NFL quarterback Aaron Rodgers, for instance, has<a href="https://www.benzinga.com/markets/cannabis/22/08/28358173/aaron-rodgers-says-ayahuasca-helped-him-achieve-best-season-of-his-career-love-himself"> credited his experience with ayahuasca</a> for improving his mental clarity and resilience.
<h3 class="wp-block-heading">A Call for Responsible Use</h3>
Despite the growing interest in psychedelics, Slater remains cautious about their misuse. "Most people figure out some way to abuse anything in life," he cautioned, stressing the importance of responsible, medically supervised use. As cities like Denver, Oakland, and Portland <a href="https://www.benzinga.com/topic/psychedelics-decriminalization">decriminalize psychedelics</a>, and Oregon <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">becomes the first state to legalize their therapeutic use</a>, there is increasing momentum for regulated access. However, federal legalization remains a contentious issue.
<h3 class="wp-block-heading">Looking Ahead</h3>
Psychedelics are on the cusp of mainstream acceptance, thanks in part to advocates like Kelly Slater. Whether for healing trauma, improving mental health, or unlocking peak performance, these substances hold significant promise. The key will be ensuring their safe, responsible integration into society's wellness toolkit.
Photo: MediaPunch/REX/Shutterstock

Psychedelics

Sports

Kelly Slater Talks Psychedelics: Healing Trauma And Unlocking Potential

Investors with a lot of money to spend have taken a bearish stance on TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TGTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for TG Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $335,818, and 6 are calls, for a total amount of $347,076.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $28.0 to $50.0 for TG Therapeutics over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for TG Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of TG Therapeutics's whale activity within a strike price range from $28.0 to $50.0 in the last 30 days. 
<h3>TG Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733172332_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$23.5</td>
<td>$19.2</td>
<td>$20.33</td>
<td>$50.00</td>
<td>$195.1K</td>
<td>1</td>
<td align="right">96</td>
</tr>
<tr>
<td>TGTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$17.0</td>
<td>$14.3</td>
<td>$14.5</td>
<td>$40.00</td>
<td>$140.6K</td>
<td>127</td>
<td align="right">97</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.6</td>
<td>$7.3</td>
<td>$7.3</td>
<td>$29.00</td>
<td>$72.2K</td>
<td>2</td>
<td align="right">170</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$7.2</td>
<td>$6.9</td>
<td>$7.2</td>
<td>$28.00</td>
<td>$71.9K</td>
<td>769</td>
<td align="right">170</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.8</td>
<td>$0.9</td>
<td>$40.00</td>
<td>$57.9K</td>
<td>1.0K</td>
<td align="right">16</td>
</tr>
</tbody>
</table>

<h3>About TG Therapeutics</h3>
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
In light of the recent options history for TG Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of TG Therapeutics</h3>
<ul>
<li>Trading volume stands at 1,278,914, with TGTX's price up by 0.07%, positioned at $34.83.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 86 days.</li>
</ul>
<h3>What The Experts Say On TG Therapeutics</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $40.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Neutral rating for TG Therapeutics, targeting a price of $22. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on TG Therapeutics, which currently sits at a price target of $43. 
&#x2A; Consistent in their evaluation, an analyst from HC Wainwright &amp; Co. keeps a Buy rating on TG Therapeutics with a target price of $55. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest TG Therapeutics options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

TGTX

This Is What Whales Are Betting On TG Therapeutics

Deep-pocketed investors have adopted a bearish approach towards Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in QCOM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 37 extraordinary options activities for Qualcomm. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 32% leaning bullish and 48% bearish. Among these notable options, 9 are puts, totaling $427,522, and 28 are calls, amounting to $1,701,088.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $310.0 for Qualcomm over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Qualcomm options trades today is 1470.91 with a total volume of 26,859.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Qualcomm's big money trades within a strike price range of $75.0 to $310.0 over the last 30 days.
<h3>Qualcomm Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733172327_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$34.95</td>
<td>$32.35</td>
<td>$33.02</td>
<td>$170.00</td>
<td>$168.5K</td>
<td>163</td>
<td align="right">61</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$24.4</td>
<td>$22.55</td>
<td>$23.59</td>
<td>$200.00</td>
<td>$141.5K</td>
<td>450</td>
<td align="right">61</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.4</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$190.00</td>
<td>$110.8K</td>
<td>1.0K</td>
<td align="right">108</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$18.2</td>
<td>$17.95</td>
<td>$18.01</td>
<td>$150.00</td>
<td>$107.8K</td>
<td>205</td>
<td align="right">60</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$35.75</td>
<td>$34.8</td>
<td>$35.22</td>
<td>$175.00</td>
<td>$105.6K</td>
<td>33</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Qualcomm</h3>
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
<h3>Present Market Standing of Qualcomm</h3>
<ul>
<li>Currently trading with a volume of 5,940,666, the QCOM's price is up by 2.79%, now at $162.96. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 58 days.</li>
</ul>
<h3>Expert Opinions on Qualcomm</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $196.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a In-Line rating on Qualcomm with a target price of $199. 
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $240. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Qualcomm, which currently sits at a price target of $195. 
&#x2A; An analyst from UBS persists with their Neutral rating on Qualcomm, maintaining a target price of $190. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $160. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Qualcomm with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

QCOM

Smart Money Is Betting Big In QCOM Options

Okeanis Eco Tankers Corp. (ECO) has released an update. Okeanis Eco Tankers Corp., a prominent player in the seaborne transportation industry, is s...

Okeanis Eco Tankers to Announce Q3 2024 Results

Okeanis Eco Tankers Non-GAAP EPS of $0.45, revenue of $84.9M beats by $23.02M

Okeanis Eco Tankers Corp. (ECO) has released an update. Okeanis Eco Tankers Corp. has announced a dividend of USD 0.45 per common share, classified...

Okeanis Eco Tankers Declares Dividend Amid Market Variations

Okeanis Eco Tankers declares $0.45 dividend

Okeanis Eco Tankers Corp. (ECO) Q3 2024 Earnings Call Transcript

DHT Holdings Q3 Earnings Preview: Room For Disappointment

Okeanis Eco Tankers: Leveraging Efficiency, Valuation, And High Dividends

Okeanis Eco Tankers Remains A Top Pick Post Earnings, Maintain Buy

Of 36 Dividend Power Dogs, 11 Are Buyable In November

Nordic American Tankers: Weak Results And Mediocre Near-Term Prospects - Hold

BWLP

CMBT

HAFN

INSW

JFIN

REFI

RWAY

SITC

STLA

STNG

TRMD

VALE

Press Releases

Okeanis Eco Tankers Corp. – Invitation to Q2 2024 Results Conference Call and Webcast

Okeanis Eco Tankers Corp. – Unaudited Condensed Financial Statements for the Second Quarter and Six-Month Period of 2024

Dividends

Okeanis Eco Tankers Corp. – Key Information relating to Q2 2024 dividend

Okeanis Eco Tankers Corp. – Ex Dividend Date

Okeanis Eco Tankers Corp. – Invitation to Q3 2024 Results Conference Call and Webcast

Okeanis Eco Tankers Corp. Reports Financial Results for the Third Quarter and Nine-Month Period of 2024

Okeanis Eco Tankers Corp. – Key Information relating to Q3 2024 dividend

Okeanis Eco Tankers Corp. – 2023 ESG Report

UPDATE – Capital Link Shipping Sectors Webinar Series - December 2024 - Dry Bulk, Container, Product Tanker, Crude Tanker, LPG, LNG Shipping

CCEC

DMCOF

EDRY

ESEA

FLNG

GOGL

NVGS

SBLK

SHIP

USEA

Ardmore Shipping Corporation Common Stock

Ardmore Shipping

Brooge Energy

BW LPG

CrossAmerica Partners LP Common Units representing limited partner interests

CrossAmerica Partners

Cool Co

DHT Holdings

Dynagas LNG Partners

Excelerate Energy, Inc. Class A Common Stock

Excelerate Energy

Flex LNG

StealthGas

Genesis Energy

Global Partners LP Common Units representing Limited Partner Interests

Global Partners

Imperial Ptrl

KNOT Offshore Partners LP Common Units representing Limited Partner Interests

KNOT Offshore Partners

Dorian LPG

Martin Midstream Partners L.P. - Common Units Representing Limited Partnership Interests

Comments

Okeanis Eco Tankers

Noticias

Últimas noticias sobre Okeanis Eco Tankers (NYSE:ECO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL